ScripGalecto Inc. ’s GB2064 has shown positive interim efficacy in the Phase IIa MYLOX-1 trial in myelofibrosis, giving weight to the inhibition of LOXL2 as an effective therapeutic strategy for the diseas
Pink SheetWhile working to progress vaccines and therapies for COVID-19, the FDA and the pharmaceutical industry are still focused on business as usual. The pandemic continues to dominate headlines, most recent
ScripGermany’s family-owned multinational Boehringer Ingelheim International GmbH (BI) is acquiring preclinical antibody assets from two biotechs, Canada’s Northern Biologics Inc. and Switzerland’s CD
Pink SheetThe US Food and Drug Administration's accelerated approval of Karyopharm Therapeutics Inc. 's Xpovio (selinexor) made headlines during the past few weeks over possibility that the agency backed the d